Your browser doesn't support javascript.
COVID-19: Clinical aspects and therapeutics responses.
Khan, Suliman; Ali, Ashaq; Shi, Hongwei; Siddique, Rabeea; Nabi, Ghulam; Hu, Junjie; Wang, Tiejun; Dong, Men; Zaman, Wajid; Han, Guang.
  • Khan S; Department of Cerebrovascular Diseases, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Ali A; Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China.
  • Shi H; Wuhan Institute of Virology, Chinese Academy of Sciences, Xiao Hong Shan No.44, Wuhan, China.
  • Siddique R; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Shabana; Key State Laboratory of Virology, School of Life Sciences, Wuhan University, Wuhan, China.
  • Nabi G; Department of Cerebrovascular Diseases, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Hu J; Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China.
  • Wang T; Wuhan Institute of Virology, Chinese Academy of Sciences, Xiao Hong Shan No.44, Wuhan, China.
  • Dong M; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Zaman W; Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences, Hebei Normal University,Shijiazhuang 050024, China.
  • Han G; Department of Gastrointestinal Surgery , Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Saudi Pharm J ; 28(8): 1004-1008, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-623558
ABSTRACT
COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retrospective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5-7 days in patients with mild symptoms with 98% recovery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: Saudi Pharm J Year: 2020 Document Type: Article Affiliation country: J.jsps.2020.06.022

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal: Saudi Pharm J Year: 2020 Document Type: Article Affiliation country: J.jsps.2020.06.022